MX2020012823A - Alcoxipiridinil indolsulfonamidas sustituidas. - Google Patents

Alcoxipiridinil indolsulfonamidas sustituidas.

Info

Publication number
MX2020012823A
MX2020012823A MX2020012823A MX2020012823A MX2020012823A MX 2020012823 A MX2020012823 A MX 2020012823A MX 2020012823 A MX2020012823 A MX 2020012823A MX 2020012823 A MX2020012823 A MX 2020012823A MX 2020012823 A MX2020012823 A MX 2020012823A
Authority
MX
Mexico
Prior art keywords
indolsulfonamides
substituted
alkoxypyridinyl
gpr17
alkoxy
Prior art date
Application number
MX2020012823A
Other languages
English (en)
Inventor
Marie Ledecq
Laurent Provins
Cécile Pegurier
Emre M Isin
Original Assignee
Ucb Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Gmbh filed Critical Ucb Pharma Gmbh
Publication of MX2020012823A publication Critical patent/MX2020012823A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se refiere a piridinil indolsulfonamidas alcoxi-sustituidas. Los compuestos son moduladores de GPR17 negativos y tienen utilidad en el tratamiento de varios trastornos asociados a GPR17.
MX2020012823A 2018-06-20 2019-06-19 Alcoxipiridinil indolsulfonamidas sustituidas. MX2020012823A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18178773.0A EP3584244A1 (en) 2018-06-20 2018-06-20 Substituted alkoxypyridinyl indolsulfonamides
PCT/EP2019/066148 WO2019243398A1 (en) 2018-06-20 2019-06-19 Substituted alkoxypyridinyl indolsulfonamides

Publications (1)

Publication Number Publication Date
MX2020012823A true MX2020012823A (es) 2021-02-15

Family

ID=62715911

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012823A MX2020012823A (es) 2018-06-20 2019-06-19 Alcoxipiridinil indolsulfonamidas sustituidas.

Country Status (14)

Country Link
US (1) US11976056B2 (es)
EP (3) EP3584244A1 (es)
JP (1) JP7371031B2 (es)
CN (1) CN112292375B (es)
CA (1) CA3101086A1 (es)
DK (1) DK3810587T3 (es)
ES (1) ES2929829T3 (es)
HR (1) HRP20221289T1 (es)
HU (1) HUE060181T2 (es)
LT (1) LT3810587T (es)
MX (1) MX2020012823A (es)
PL (1) PL3810587T3 (es)
PT (1) PT3810587T (es)
WO (1) WO2019243398A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020254289A1 (en) * 2019-06-17 2020-12-24 Ucb Pharma Gmbh N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
CN112375027B (zh) * 2020-12-07 2023-03-31 中国药科大学 吲哚磺酰胺类衍生物及其医药用途
KR20230152006A (ko) * 2021-02-26 2023-11-02 에프. 호프만-라 로슈 아게 신규 피리미딘-2-일 설폰아미드 유도체
EP4311828A1 (en) * 2022-07-26 2024-01-31 Basf Se A process for the photolytic chlorination of 3-halopyridine with molecular chlorine
WO2023241960A1 (en) * 2022-06-15 2023-12-21 Basf Se A process for the photolytic chlorination of 3-halopyridine with molecular chlorine
WO2024017855A1 (en) * 2022-07-20 2024-01-25 F. Hoffmann-La Roche Ag Novel isothiazol-3-yl and isoxazol-3-yl sulfonamide compounds
WO2024017858A1 (en) * 2022-07-20 2024-01-25 F. Hoffmann-La Roche Ag Novel naphthyl and isoquinoline sulfonamide derivatives
WO2024017863A1 (en) * 2022-07-20 2024-01-25 F. Hoffmann-La Roche Ag Novel pyrimidinyl and triazinyl sulfonamide derivatives
WO2024017857A1 (en) 2022-07-20 2024-01-25 F. Hoffmann-La Roche Ag Novel imidazopyridine and pyrazolopyridine sulfonamide derivatives
WO2024017856A1 (en) 2022-07-20 2024-01-25 F. Hoffmann-La Roche Ag Novel isoquinolinone, pyrrolopyridinone and thienopyridinone sulfonamide derivatives
WO2024023129A1 (en) * 2022-07-28 2024-02-01 F. Hoffmann-La Roche Ag Novel 7-substituted indole sulfonamide derivatives
WO2024023128A1 (en) * 2022-07-28 2024-02-01 F. Hoffmann-La Roche Ag Novel 7-substituted indole sulfonamide derivatives
WO2024042147A2 (en) * 2022-08-26 2024-02-29 F. Hoffmann-La Roche Ag Novel deuterated pyrimidin-2-yl sulfonamide derivatives
WO2024115733A1 (en) * 2022-12-02 2024-06-06 Rewind Therapeutics Nv Fused pyrrolyl-sulfonamide compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
SE9904750D0 (sv) 1999-12-23 1999-12-23 Pharmacia & Upjohn Ab New formulation, use and method
JP4685767B2 (ja) 2004-04-27 2011-05-18 武田薬品工業株式会社 Ｇタンパク質共役型レセプタータンパク質の新規リガンドとその用途
ITMI20042007A1 (it) 2004-10-21 2005-01-21 Consiglio Nazionale Ricerche "modulatori del ricettore gpr17 e loro impieghi terapeutici"
JP5225100B2 (ja) 2005-12-20 2013-07-03 テイコク ファーマ ユーエスエー インコーポレーテッド インドールセロトニン受容体作動薬の経皮投与方法及びそれを使用するための経皮組成物
WO2009000262A1 (de) 2007-06-25 2008-12-31 Acino Ag Elektrophoretisches transdermales applikationssystem
WO2010054307A1 (en) * 2008-11-07 2010-05-14 The Cleveland Clinic Foundation Compounds and methods of promoting oligodendrocyte precursor differentiation
WO2011113032A2 (en) 2010-03-11 2011-09-15 Swinford Jerry L Method and apparatus for washing dowhole tubulars and equipment
EP2567698B1 (en) * 2011-09-07 2014-02-12 Rheinische Friedrich-Wilhelms-Universität Bonn GPR 17 agonists and screening assay
WO2013167177A1 (en) 2012-05-09 2013-11-14 Universita' Degli Studi Di Milano Gpr17 receptor modulators.
CN110545804A (zh) 2016-09-24 2019-12-06 华盛顿大学 Sarm1 nad酶活性抑制剂及其用途
TWI754702B (zh) * 2016-12-28 2022-02-11 德商Ｕｃｂ製藥有限公司 （氮雜）吲哚－和苯並呋喃－３－磺醯胺類

Also Published As

Publication number Publication date
ES2929829T3 (es) 2022-12-01
EP4086248A1 (en) 2022-11-09
JP2021527696A (ja) 2021-10-14
HUE060181T2 (hu) 2023-02-28
EP3810587A1 (en) 2021-04-28
CN112292375A (zh) 2021-01-29
EP3584244A1 (en) 2019-12-25
LT3810587T (lt) 2022-11-25
US20210214337A1 (en) 2021-07-15
EP3810587B1 (en) 2022-08-10
PL3810587T3 (pl) 2023-02-06
US11976056B2 (en) 2024-05-07
HRP20221289T1 (hr) 2022-12-23
CN112292375B (zh) 2023-12-05
DK3810587T3 (da) 2022-10-31
CA3101086A1 (en) 2019-12-26
JP7371031B2 (ja) 2023-10-30
WO2019243398A1 (en) 2019-12-26
PT3810587T (pt) 2022-11-14

Similar Documents

Publication Publication Date Title
MX2020012823A (es) Alcoxipiridinil indolsulfonamidas sustituidas.
MX2020012173A (es) Piridinil y pirazinil-(aza)indolsulfonamidas.
MX2018015656A (es) Compuestos heterociclicos como antibacterianos.
CR20210335A (es) Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular la hemoglobina
PH12020551140A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12020551144A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2020013468A (es) Anticuerpos il-11ra.
MX2017002271A (es) Composiciones y metodos para el tratamiento de trastornos neurologicos.
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
MX2022007994A (es) Derivados de arilciclohexilamina y su uso en el tratamiento de trastornos psiquiátricos.
MX2019015563A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
MX2019005779A (es) Metodos para tratar trastornos del desarrollo y/o trastornos convulsivos con flupirtina.
MY182342A (en) N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of nr2b
PH12017502224A1 (en) Positive allosteric modulators of muscarinic md receptor
ZA202002779B (en) Dantrolene prodrugs and methods of their use
EP3618824A4 (en) USE OF N-ACETYLCYSTONE FOR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
MX2021002754A (es) Tratamiento del autismo y trastornos dentro del espectro del autismo con composiciones de biotina.
EP3877412A4 (en) USE OF CLAZAKIZUMAB TO DESENSITIZE AND IMPROVE KIDNEY TRANSPLANTATION IN HLA-SENSITIZED PATIENTS
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
EP3624801A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF COMPLICATIONS AND DISORDERS RELATED TO VON WILLEBRAND FACTOR
PH12016501658A1 (en) Sialylated glycoprotein compositions and uses thereof
EP3533451A4 (en) APPLICATION OF PAEENIFLORIN-6'-O-BENZENE SULFONATE IN MEDICINE FOR THE TREATMENT OF SJÖGREN SYNDROME
EP3761979A4 (en) USE OF GABOXADOL TO TREAT SUBSTANCE ABUSE